سعر اليمبوسيس 5 مجم 30 قرص 2023

Egyptian apixaban 5 mg film-coated tablets, pack of 30 (anticoagulant).

• Reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation; prophylaxis of DVT after hip/knee replacement; treatment of DVT/PE and reduction of recurrent DVT/PE in adults (US Eliquis labeling).Population: Adults per US labelDailyMed (U.S. NLM)

• Most common adverse reactions in adults related to bleeding (>1%) (US Eliquis).International label, same formulation · DailyMed (U.S. NLM)

• Active pathological bleeding; severe hypersensitivity to apixaban (US Eliquis).International label, same formulation · DailyMed (U.S. NLM)

• Boxed warnings: premature discontinuation increases thrombotic risk; spinal/epidural hematoma with neuraxial anesthesia. Serious bleeding risk; not recommended with prosthetic heart valves or triple-positive APS (US Eliquis).International label, same formulation · DailyMed (U.S. NLM)

• Combined P-gp and strong CYP3A4 inhibitorsMajorIncrease apixaban exposure — reduce 5/10 mg doses by 50%; avoid with 2.5 mg dose (US Eliquis).DailyMed (U.S. NLM)
• Combined P-gp and strong CYP3A4 inducersMajorDecrease apixaban exposure — avoid concomitant use (US Eliquis).DailyMed (U.S. NLM)
• Anticoagulants / antiplatelets / NSAIDs / SSRIs / SNRIsMajorIncreased bleeding risk with coadministration (US Eliquis).DailyMed (U.S. NLM)

• Limited human data insufficient to inform drug-associated risk; treatment may increase bleeding risk in pregnancy and delivery; not recommended in pregnancy (US Eliquis PLLR).International label, same formulation · DailyMed (U.S. NLM)
• No data on presence in human milk; breastfeeding not recommended during treatment (US Eliquis).International label, same formulation · DailyMed (U.S. NLM)

• Apixaban: Selective, reversible inhibitor of free and clot-bound factor Xa and prothrombinase activity, decreasing thrombin generation; no direct effect on platelet aggregation (US label).